RESULT-Hip. The impact of restrictive compared with liberal transfusion strategy on cardiac injury and death in patients undergoing surgery for hip fracture Authors: The RESULT Hip Study Group Published: 2026 ABSTRACT AimsHip fracture is a global health issue. Complications are common, leading to reduced quality of life or death. These occur more frequently if anaemia is present. We hypothesize that correcting anaemia in the perioperative period may decrease major adverse cardiac events (MACE) and death after hip fracture.MethodsThis multicentre prospective randomized trial compares transfusion strategies after hip fracture in patients aged ≥ 60 years. We initially planned to randomize 1,984 participants with anaemia, defined as haemoglobin ≤ 90 g l-1, to one of two transfusion strategies: liberal transfusion (aim haemoglobin 90 g l-1 to 110 g l-1), or restrictive transfusion (aim 75 g l-1 to 90 g l-1). The intervention lasts from randomization to hospital discharge or 30 days post randomization, whichever is soonest. The primary outcome measure was a composite of death or MACE adjudicated by blinded clinical experts. Secondary outcomes included all-cause mortality and quality of life, evaluated at 120 days. Cost-effectiveness and health economic evaluation will also be reported.ResultsThis trial was funded by the National Institute for Health and Care Research, HTA award (National Institute for Health and Care Research (NIHR) 130875) and registered at ISRCTN 28818784. Ethical approval was obtained to recruit patients in the UK. As recruitment fell short of the initial target, and following consultation with the funder, we refined our primary outcome to include myocardial injury after non-cardiac surgery (MINS), and reduced the required sample size to 842.ConclusionRecruitment commenced on 10 June 2022. The first participant was recruited on 16 June 2022. We will engage clinicians and healthcare planners to implement the findings. We plan to recruit until 31 October 2026. Results will be disseminated to clinicians, policymakers, patients, and the public.Cite this article: Bone Jt Open 2026;7(10):1342–1351. Introduction Hip fracture is a major challenge facing populations and healthcare systems. Globally, 9.58 million people suffered hip fracture in 2019, and this caused 1.84 million years lived with disability.1 The global cost has been estimated at 1.4% of the total healthcare burden in developed economies.2 Hip fracture care is a major acute activity in all UK NHS Trusts, with one in 45 of NHS hospital beds dedicated to this surgical population. In the UK, over 70,000 people sustained a hip fracture in 2023,3 at an estimated annual cost of over £1 billion.4 Hip fracture has a significant impact on health. People with this condition are typically elderly and multimorbid, including cardiovascular disease, and renal and cognitive dysfunction. The mean length of hospital stay in the UK is 15 days, and 19% of those who survive do not return to their original residence and have high rates of increased dependency.3 The rate of chronic cardiovascular disease (CVD) is consistently estimated at over 60% in this population.5-7 In 2024 the UK 30-day mortality for hip fracture was 5.1%, rising to 30% at one year.3 Postoperative complications include cardiac events, acute kidney injury (AKI), delirium, and infection.5,8-10 Cardiac and infectious complications are the leading causes of acute hospital mortality in hip fracture.11 The rate of myocardial infarction (MI) meeting standard definitions is estimated at 3% to 6%.7,12 The rate of myocardial injury after non-cardiac surgery (MINS, an elevated serum troponin which does not meet universal criteria for MI)13 is approximately 40% in the orthogeriatric population.12 MINS is independently and strongly associated with both short- and long-term mortality,14 and data from observational studies suggest that in patients with anaemia, this is even higher.5,11 Other cardiac complications (e.g. arrythmias or pulmonary oedema) are also common, at between 6% to 10%.12,15 Anaemia is common in people with hip fracture and is multifactorial, arising from chronic disease and blood loss at the time of injury and surgery. Red blood cell (RBC) transfusion rates are also high in this group, at approximately 30%.16,17 Restrictive transfusion strategies are recommended in stable hospitalized adults,18 but uncertainty exists for important patient sub-groups, notably those with coexisting cardiovascular disease. RBC transfusions increase haemoglobin levels with the belief that this may increase oxygen delivery to the tissues and improve clinical outcomes. In this population, clinical belief suggests this may prevent cardiac complications, improve mobilization, and reduce hospital stay.19 However, blood components are biological agents, with uncertain risks including transfusion-associated circulatory overload (TACO), immunosuppression, and immunomodulatory effects which may increase infectious complications. Systematic reviews have considered the issue of transfusion threshold in relevant populations:20 fractured neck of femur,6,8,17 those undergoing surgery,21,22 or older patients.23 Across trial populations, there is no evidence that restrictive strategies are associated with worse clinical outcomes; however, the range of transfusion triggers used by each study varies, with no standard definition of a restrictive or liberal strategy – people with cardiac disease or other clinical contexts were excluded or under-represented from many of the large trials in this area. Targeted systematic review suggests that people with chronic cardiac disease experience higher rates of MI and a trend towards higher mortality when managed with restrictive transfusion strategies.22 Current recommendations from professional bodies vary in their recommendations for RBC transfusion in people with hip fracture. The National Institue for Health and Care Excellence (NICE) recommends a RBC transfusion threshold at a haemoglobin concentration of 70 g l-1 for stable hospitalized adults.18 The American Association of Blood Banks guideline (AABB) recommends a restrictive RBC transfusion threshold of 70 g l-1 to 75 g l-1.24 The 2021 Association of Anaesthetists (AoA) review of hip fracture suggests that perioperative haemoglobin concentration in frailer patients should be kept above 90 g l-1, or 100 g l-1 for patients with CVD or who fail to remobilize on the first postoperative day.25 Contradictory recommendations illustrate current uncertainties and the need for high-quality evidence to guide transfusion strategy in this group of patients, and all acknowledge the need for further research. Aims and objectives RESULT-Hip is a randomized trial of two transfusion strategies in people with hip fracture. We hypothesize that a liberal postoperative transfusion strategy will reduce death and major cardiovascular complications, and be more cost-effective in people with hip fracture and anaemia, compared with currently recommended more restrictive transfusion strategies. The primary objective is to determine if a liberal postoperative transfusion strategy, compared with a restrictive transfusion strategy, will reduce death and major cardiovascular complications in people with hip fracture and anaemia. Secondary objectives are to determine if a liberal postoperative transfusion strategy, compared with a restrictive transfusion strategy, will improve quality of life at 120 days and reduce costs in people with hip fracture and anaemia. Data collected at each timepoint are summarized in Table I. Table I.Complete dataset to be collected for RESULT-Hip.TimepointVariableAt randomizationAgeSexPre-existing cardiovascular diseaseHaemoglobinBaselineCHI or NHS numberEthnicityResidential status (own home/sheltered housing, residential care, nursing care)Prefracture mobility statusAMTS or AMT426Fracture type, operation performed, date and duration of surgery, ASA grade,27 mode of anaesthesiaHaemoglobin: pre- and postoperatively, intraoperative red cell transfusion, blood-sparing technology usage.ECGTroponin concentrationComorbidities: dementia, malignancy, cardiovascular disease, cardiovascular risk factors (vascular disease, diabetes, hypertension, kidney disease), atrial fibrillationMedications: cardiac, anticoagulant, and anti-platelet medicationsResults: Creatinine and eGFRNottingham Hip Fracture Score28Rockwood Clinical Frailty Scale4 ‘A’s Test29Health-related quality of life (EQ-5D-5L)During hospital stayHaemoglobin and U&E resultsPre- and post transfusion haemoglobin (each transfusion episode)Troponin concentrations day 1 and day 3 (window days 1 to 5)ECG day 3 (window day 2 to 5)Number and volume of units of blood transfused, plus G number4AT day 1 and day 3 (window days 1 to 5)Postoperative complications using Hip Fracture Post-Operative Morbidity SurveyEpisodes of chest pain days 0 to 330 days post-randomizationRecord of all red cell transfusions administered, G numberLength of hospital stayMACEEvidence of cardiac complications: non-trial cardiac investigations carried out locally, new stroke, pulmonary embolus.All complicationsAKIMortalityHealth-related quality of life (EQ-5D-5L)Health services use (Health economics questionnaire)120 days post randomizationAcute hospital discharge destinationEmergency readmission, speciality, and locationMortalityCause of death (if applicable)MACE (if not previously recorded)ReoperationTotal number of hospitals, ICU, HDU bed days.Place of residence (using NHFD)Mobility (using NHFD)Health-related quality of life (EQ-5D-5L)Health services use (Health economics questionnaire)AKI, acute kidney injury; AMTS, Abbreviated Mental Test Score; ASA, American Society of Anesthesiologists; CHI, Community Health Index; ECG, 12 lead electrocardiogram; eGFR, estimated glomerular filtration rate; EQ-5D-5L, EuroQol five-dimension five-level questionnaire; HDU, high dependency care unit; ICU, intensive care unit; MACE, major adverse cardiac events; NHFD, Nottingham Hip Fracture Database; U&E, urea and electrolytes. Complete dataset to be collected for RESULT-Hip. AKI, acute kidney injury; AMTS, Abbreviated Mental Test Score; ASA, American Society of Anesthesiologists; CHI, Community Health Index; ECG, 12 lead electrocardiogram; eGFR, estimated glomerular filtration rate; EQ-5D-5L, EuroQol five-dimension five-level questionnaire; HDU, high dependency care unit; ICU, intensive care unit; MACE, major adverse cardiac events; NHFD, Nottingham Hip Fracture Database; U&E, urea and electrolytes. Methods This manuscript was written in accordance with the ‘Standard Protocol Items: Recommendations for Interventional Trials’ (SPIRIT) guidelines.30 Trial design and setting This is a multicentre, parallel-group randomized controlled clinical and cost-effectiveness trial of two RBC transfusion strategies – liberal and restrictive. Participants are allocated to a treatment arm using a web-based allocation system at random in a 1:1 ratio. The trial included a six-month internal pilot phase to assess recruitment and compliance with trial protocols. The trial is being conducted in UK acute hospital trusts that manage people with hip fracture as part of their usual emergency workload. Eligibility Inclusion criteria: adults aged ≥ 60 years; admitted to an acute hospital unit for operative management of hip fracture; and anaemia defined as haemoglobin concentration ≤ 90 g l-1. Exclusion criteria: objection to RBC transfusion; inability to obtain consent (from patient or in accordance with appropriate mental capacity legislation); patients for nonoperative management or not expected to survive 48 hours; new or suspected acute coronary syndrome during current admission; rapid or uncontrolled blood loss resulting in haemodynamic instability; and chronic anaemias requiring repeated transfusion (e.g. myelodysplasia or bone marrow failure syndromes). Recruiting sites screen people who meet age and fracture criteria as they attend hospital. Screening takes place from admission up to and including seven days postoperatively. Potential participants are approached to provide consent to the trial. If a haemoglobin measurement triggers inclusion in the study, by falling to ≤ 90 g l-1, then the patient is randomized. Trial interventions Randomized participants are assigned to one of two arms determining when transfusion is commenced: restrictive (haemoglobin (Hb) ≤ 75 g l-1 triggers transfusion, range 75 g l-1 to 90 g l-1) or liberal (Hb ≤ 90 g l-1 or less triggers transfusion, range 90 g l-1 to 110 g.l-1). Participants remain in their transfusion arm for the duration of acute hospital stay (or for 30 days post-randomization: whichever is shorter). Participants randomized to the liberal arm immediately receive one unit of red blood cells to keep their haemoglobin within the designated range. Participants randomized to the restrictive arm do not receive a blood transfusion unless their haemoglobin falls to ≤ 75 g l-1 . Both groups have single-unit transfusions to keep their haemoglobin within the target range, repeated as necessary. If a participant requires an intraoperative blood transfusion, adherence to the protocol is recommended where clinically acceptable. The use of point of care haemoglobin measurement is accepted to target transfusion. In the case of major blood loss in the operating theatre or elsewhere, there is a temporary suspension of the study protocol, and the clinical team may transfuse at physician discretion. These events are recorded as protocol deviations. National specifications for red cell units are available. All red cell components were administered according to local hospital guidelines, informed by national guidance. All participating centres contributed to UK haemovigilance for safety reporting. Patients are followed up for 120 days, after which usual local follow-up arrangements apply. There is no compensation offered to trial participants. Outcome measurements The primary outcome for this trial is death, or major adverse cardiac events (MACE) or new MINS within 30 days of surgery. MACE is defined as any combination of the following: myocardial infarction (MI, meeting fourth Universal Definition);13 new arrhythmia resulting in a fall in mean arterial pressure of > 20% and requiring treatment; non-fatal cardiorespiratory arrest (Resuscitation Council UK definitions);31 cardiogenic pulmonary oedema. New MINS is defined according to clinical practice guidelines as an elevated postoperative cardiac troponin with one or more measurements above the sex-specific 99th percentile upper reference limit with a rise/fall pattern indicative of acute myocardial injury occurring in the first 30 days (and typically within 72 hrs) of non-cardiac surgery.32 Acute myocardial injury is attributable to a presumed ischaemic mechanism, but symptoms of ischaemia as they are masked by sedation or analgesia in the perioperative setting, and ischaemic features (e.g. electrocardiographic changes) are not required. To maximize validity and consistency, all participants have troponin measured at randomization (baseline), and then twice more in the first five days after randomization with all tests being at least 24 hours apart. Electrocardiographs are performed at baseline and repeated once in the first five days. The primary outcome is determined centrally by a blinded expert adjudication team. Secondary outcome measures collected at 30 days are: all-cause mortality, myocardial injury, individual MACE components (including type of arrhythmia), acute kidney injury, infection, delirium, proportion of participants transfused; volume of blood transfused per patient, discharge destination, acute hospital length of stay, and health-related quality of life (HRQoL). Secondary outcome measures collected at 120 days are: all-cause mortality, secondary care costs, unplanned hospital readmissions, mobility (defined by National Hip Fracture Database (NHFD)) residential status (defined by NHFD),3 health-related quality of life, health services resource use. A description of the patient pathway through the study is given in Figure 1 and data collected in Table I. Study flowchart and participant timeline. ECG, electrocardiogram; EQ-5D-5L, EuroQol five-dimension five-level questionnaire; Hb, haemoglobin; MINS, myocardial injury after non-cardiac surgery; U&Es, urea and electrolytes. Randomization and blinding Participants are randomized by remote computer to ensure allocation concealment. Allocation is in a 1:1 ratio with stratification by centre, age (< 80 years vs ≥ 80 years) and pre-existing diagnosis of cardiovascular disease. Randomization is performed using a web-based randomization system. Due to the nature of the intervention, trial participants and local study teams are not blinded to the study arm allocation. However, the primary outcome assessment is adjudicated by a panel blinded to treatment allocation. A six-month internal pilot was included in the study design. Quantitative internal pilot success criteria were predetermined with an aim to open ten sites, recruiting > 130 patients and with > 90% protocol adherence. Process evaluation We undertook a process evaluation during the pilot phase to establish the extent to which the intervention was implemented as intended across different sites. This included qualitative interviews with research staff at pilot sites to identify facilitators and barriers to recruitment. The process evaluation informed feasibility and guided changes required to maximize recruitment and fidelity of the trial protocol for the main study. Statistical analysis Sample size calculations were informed by our pilot study,11 the 2019 NHFD Annual Report,33 and another large trial of transfusion in hip fracture.7 In people with hip fracture, we estimated 30-day all-cause mortality to be 7%, and MACE to be 10%. In our pilot trial, rates of myocardial injury and death were higher in anaemic participants, and individual outcome components may occur concurrently in some participants.11 It was hypothesized that systematic cardiac troponin and electrocardiogram (ECG) measurement will increase MI detection compared with previous studies. We considered an absolute risk reduction (ARR) of 5% in the primary outcome to be a realistic meaningful effect size that would change practice (33% relative risk reduction, RRR). Importantly, this would represent a number needed to treat (NNT) of 20 for every patient receiving liberal transfusion to avoid an unfavourable outcome compared with the restrictive group. We recognized limitations of a dichotomous composite primary outcome – components treated equally may have differing importance to patients and clinicians. Less severe parts of the composite may occur more frequently and might dominate overall event rates. We planned to address this with an ordinal ranking of the possible outcomes at 30 days (best to worst) according to severity and importance. With an assumed 30-day mortality rate of 7% and MACE at 30 days of 10%, to detect a 30% RRR (corresponding to a log-odds-ratio of approximately 0.64) and assuming proportional odds between the liberal and restrictive groups, we initially planned a sample size of 884 participants in each arm, using a Mann-Whitney U test with a 5% two-sided significance level and 90% power. Allowing for a 10% dropout rate, we initially proposed to recruit 982 per group, a total sample size 1,964 participants. Trial recruitment did not progress as planned and because it was unlikely that the trial would recruit to this target within the planned timeframe, the funder agreed to a redesign of the trial primary outcome to include MINS and to reduce trial power to 80%. We revised the ordinal ranking of the possible outcomes at 30 days (1 best; 6 worst) according to severity/importance: 1) no death, no MACE, no new MINS; 2) no death, no MACE, but new MINS; 3) no death ≥ 1 MACE; 4) death, no MACE, no new MINS; 5) death, plus new MINS; 6) death plus ≥ 1 MACE. We also plan to report rates of MACE components and new MINS separately. We estimated rate of new MINS of 20% based on outcome data for the first 76 trial patients and existing published observational data.12 To detect a 30% RRR (corresponding to a log-odds-ratio of approximately 0.64) and assuming proportional odds between the liberal and restrictive groups, we calculated a revised sample size of 379 participants in each arm, using a Mann-Whitney U test with a 5% two-sided significance level and 80% power. Allowing for a 10% dropout rate, we propose to recruit 421 participants per group, total sample size 842 participants. Primary outcome analysis: As described above, primary analysis will use the Mann-Whitney U test, under an intention-to-treat principle. Koch’s non-parametric analysis of covariance (ANCOVA) will be considered as a potentially more powerful analysis, adjusting for the stratification variables included in the randomization i.e., centre, age (< 80 vs ≥ 80 years), and pre-existing CVD.34 If appropriate, analyses will be adjusted for centre as a random effect. Patients with pre-existing CVD may be on anticoagulant or antiplatelet drugs at the time of randomization and this might affect the rate of bleeding and anaemia. On review of baseline characteristics, the extent of the association between pre-existing CVD and anticoagulant use will be assessed and, if it is found that anticoagulant use is not strongly associated with pre-existing CVD, then it will be included as an additional covariate in all adjusted analyses. As a secondary analysis, we will assess the primary outcome using an ordinal logistic mixed-effects regression. We will explore the robustness of the findings to any missing data using multiple imputation according to Rubin’s approach under an assumption of missing at random. To address the possibility that any component of the primary outcome (particularly atrial fibrillation (AF) or new MINS) is much more prevalent in the trial than expected and dominates the primary composite outcome, we propose the following: all the individual components of MACE and new MINS will be reported as secondary outcomes and an a priori sensitivity analysis is undertaken with the AF and new MINS components of the primary outcome removed. This will be prespecified in the statistical analysis plan when developed and proposed as a secondary analysis. As a supplementary analysis based on the primary outcome, we will maximize the value of information from the RESULT-Hip trial by using the confidence distribution approach as outlined by Marschner.35 This approach will be used to make confidence probability statements about the treatment effect that are analogous to posterior probability statements generated from a Bayesian analysis, which will aid interpretability of the trial results. We will estimate the (confidence) probability that the true common odds ratio is greater than 1, 1.1, and/or 1.2, based on the results output from the ordinal regression analysis. Secondary outcomes will be analyzed using logistic regression for binary outcomes and linear regression for normally distributed continuous outcomes. Continuous outcomes that are not normally distributed will be analyzed using appropriate non-parametric techniques. Time to event data will be analyzed using an appropriate survival model (e.g. Cox proportional hazards). Prespecified sub-group analyses will explore effects in relation to sex, age (< 80 vs ≥ 80 years), presence of pre-existing CVD, and use of anticoagulant and antiplatelet drugs. These will be analyzed as per the primary outcome but including a covariate/treatment interaction. No interim analysis is planned. In terms of health economic analysis, we plan a cost-consequence analysis (CCA) of the 120-day observed trial period, and longer-term economic modelling. NHS and personal social services (PSS) will be collected, including details of the index admission, readmissions and other healthcare contacts, and care packages. These will be combined with standard UK price weights to generate costs,36 and be presented as additional contextual information alongside health outcomes (including the EuroQol five-dimension five-level questionnaire (EQ-5D-5L))37 without attempting to combine data and estimate incremental cost per quality-adjusted life-year (QALY). The formal assessment of long run cost-effectiveness will be undertaken using decision analytic modelling to account for potential health and cost implications of transition to care home, other rehabilitation programmes, or care in the community. To maximize UK policy relevance, the model will follow NICE reference case recommendations including: adoption of an NHS and PSS costing perspective; cost-utility approach (results presented in terms of incremental cost per QALY calculated from EQ-5D-5L data); discount rate of 3.5% for both costs and QALYs; and the use of probabilistic sensitivity analysis (PSA), most likely generated via a method of moments approach.38 Data collection and management Data are entered locally into an electronic case report form designed specifically for the trial. Anonymized screening data are collected at each site and entered onto the central screening log database managed by the Edinburgh Clinical Trials Unit (ECTU). Source data from trial sites are inputted directly into the electronic database by the local research team or collected on case report forms and paper questionnaire proformas before being entered into the secure, trial-specific database hosted by ECTU (Research Electronic Data Capture (REDCAP), Vanderbilt University, USA). Clinical data are collected from local records during the participants inpatient stay in hospital. Review of the notes at 30 days provides primary and secondary outcome measures. The 30-day and 120-day follow-up questionnaires and data are collected by local teams and recorded on the electronic database. Deidentified ECGs are scanned to the ECTU database for later primary outcome analysis. Blood samples for cardiac troponin measurement are processed and stored at local sites before transfer to the University of Edinburgh for batch analysis in a core laboratory using the same high-sensitivity assay (ARCHITECT STAT high-sensitivity cardiac troponin I, Abbott Laboratories, USA). Ethics and dissemination Ethics The study is being conducted in accordance with the principles of the 1996 Declaration of Helsinki,39 International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines. The study has been reviewed and approved by Scotland A REC (22/SS/001) and NW Haydock REC (22/NW/0065) in February and March 2022, respectively. Health Research Authority (HRA) approval was issued on 10 May 2022. Monitoring and safety An independent data monitoring and ethics committee (DMEC) has been established to oversee the safety of participants in the trial. Adverse event and serious adverse event reporting, audit, and monitoring follows the sponsors standard operating procedures.40 The requirement for haemovigilance is recognized, and transfusion-related adverse events or reactions and serious transfusion-related adverse reactions are recorded and reported in accordance with the definitions of serious hazards of transfusion (SHOT).41 Data protection All investigators and study site staff involved with this study must comply with the requirements of the appropriate data protection legislation (including the General Data Protection Regulation and Data Protection Act) about the collection, storage, processing, and disclosure of personal information. Published results will not contain any personal data and be of a form where individuals are not identified, and reidentification cannot occur. Incapacitated adults It is considered very important to the utility and applicability of results from this trial that all adults presenting with hip fracture can participate in this trial. Thus, the trial has been designed to include the large proportion of older hip fracture patients who do not have capacity to consent to the study. These patients, their families, and advocates are approached as outlined in Figure 2, to facilitate maximum inclusion in the trial. Process for enrolling patients without capacity. Consent pathways that align with the Mental Capacity Act (Northern Ireland) 2016, the Mental Capacity Act 2005 (England and Wales), and Adults with Incapacity (Scotland) Act 2000 have been reviewed and are used in the trial. A personal consultee is identified for patients without capacity in England, Wales, and Northern Ireland, and where a timely decision is not available within an appropriate timeframe a nominated consultee is approached. In Scotland, the welfare attorney, guardian, or nearest relative is consulted. Dissemination Informing and engaging patients and public Active engagement with our patient partners and the Patient, Carer and Public Involvement and Engagement (PCPIE) Group of Royal College of Anaesthetists will ensure that the results of the trial are disseminated to patients and the public. An accessible trial summary, including infographics, will be made available to trial participants. In addition, findings will be made more widely available by presentation at the INVOLVE conference and liaising with identified service user groups. Videos and infographics will communicate our trial findings to the public via mainstream media. Implementation of findings All trial results will be published in a National Institute for Health and Care Research (NIHR) monograph and submitted to high impact international journals, aimed at a wide clinician audience to ensure maximum reach. Our findings will also be presented at local, national, and international anaesthetic, surgical, haematology, and geriatric medicine meetings, including key stakeholders, e.g. relevant royal colleges, professional societies, and national audits. This will capture an extremely large audience of related specialists. Strong evidence supporting safety and effectiveness will be of widespread interest to policymakers and funders as well as patients and clinicians. We anticipate our findings will be included in updated systematic reviews and guidelines. Specifically, we anticipate our findings will be rapidly included into the NICE transfusion guideline (NG24) and hip fracture management guideline (NG124). Patient and public involvement The trial was designed with a patient and public involvement (PPI) representative coapplicant, with active involvement in the study during recruitment and membership of oversight groups. Patient representatives were fully involved in the trial design and delivery: the National Institute of Academic Anaesthesia (NIAA) and Health Services Research Centre (HRSC) Patient, Carer & Public Involvement and Engagement (PCPIE) group was consulted and provided detailed feedback and recommendations. A series of improvements to the patient facing documentation for the trial were recommended and implemented. The PCPIE group was keen to promote PPI involvement in the consent process, sharing information about blood transfusion and plans for dissemination of results to participants and public after completion of the trial. We have an active patient advisory group who will continue to engage PPI representation throughout the trial and will be involved in the analysis, publication, and dissemination of the trial phase after analysis. We intend to utilize their expertise to produce plain English summaries and explanations of our results. Discussion RESULT-Hip is a randomized trial investigating the effect of two transfusion strategies on death and major cardiovascular complications in people with hip fracture and anaemia. Hip fracture remains a common condition affecting many patients and their families, and is one of the largest single groups receiving RBC transfusions annually. Prevention of complications and poor outcomes could have a major impact on the incidence of morbidity and mortality, hospital stay, quality of life, and healthcare costs. Evidence-based guidance to deliver best patient care in this area will be welcomed by clinicians and may have an important impact on outcomes and postoperative quality of life. The impact of transfusion strategies on HRQoL is a major unmet research need.42 The trial will recruit participants between 2022 and 2026. The results of this trial will be made available publicly after analysis and publication. It is anticipated that the results will inform future clinical guidelines and management. Take home message - RESULT-Hip is a UK multicentre trial of blood transfusion thresholds in patients with hip fracture. - The primary outcome is a composite of death and cardiac complications. - This study is important as the evidence for transfusion in this group of patients is considered weak, and both clinical guidelines and practice vary. - The results will inform best practice for one of the largest groups receiving blood transfusions in the NHS.